Brief: 4DMT To Present Interim Clinical Data From Inglaxa Phase 1/2 Trials Of 4D-310 For Fabry Disease Cardiomyopathy At 19Th Annual Worldsymposium
16/02/2023 23:11
Feb 16 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT TO PRESENT INTERIM CLINICAL DATA FROM INGLAXA PHASE
1/2
TRIALS OF 4D-310 FOR FABRY DISEASE CARDIOMYOPATHY AT 19TH ANNUAL
WORLDSYMPOSIUM™
Source text for Eikon: ID:nGNX57V5Gf
Further company coverage: FDMT.O
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings